Journal
LANCET HAEMATOLOGY
Volume 7, Issue 8, Pages E601-E612Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S2352-3026(20)30205-2
Keywords
-
Categories
Funding
- National Cancer Institute
- National Cancer Institute of the National Institutes of Health [P30 CA016359]
- MRC [MC_UU_12009/11, G1000729, MR/L008963/1, MC_U137961146, MC_UU_00016/11] Funding Source: UKRI
Ask authors/readers for more resources
The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available